會暢通訊(300578.SZ):全資孫公司北京盈開註銷完成
格隆匯 8 月 6日丨會暢通訊(300578.SZ)公佈,為進一步整合和優化現有資源配置,降低管理成本,提高整體經營效益,公司對全資孫公司北京盈開科技有限公司(以下簡稱“北京盈開”)予以清算註銷。
根據《深圳證券交易所創業板股票上市規則》、《公司章程》及《子公司管理制度》,本次註銷事項在總經理審批權限範圍內,無需提交公司董事會和股東大會審議。本次註銷全資孫公司不構成關聯交易,也不構成《上市公司重大資產重組管理辦法》規定的重大資產重組。
公司已於近日收到北京市朝陽區市場監督管理局下發的《註銷核准通知書》,北京盈開的註銷手續已完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.